Practice question
Question
Imatinib is used in cancer therapy because it inhibits
Explanation
ATP-binding site of BCR–ABL kinase, is consistent with established principles of cell signaling, receptor pharmacology and cellular regulation. Experimental measurements of binding parameters, genetic loss-of-function studies and pharmacological interventions all converge on the same interpretation. Related options address neighboring concepts but do not satisfy the precise criterion stated in the question.